Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brainwaves under medication: revealing class-specific neural signatures of psychotropic medication from 24,000 EEGs.

EBioMedicine·2026
Same author

ZnCdO:Eu Epitaxially Grown Alloys for Self-Powered Ultrafast Broadband Photodetection.

ACS applied materials & interfaces·2026
Same author

Prevalence and Clinical Correlates of Obstructive Sleep Apnea in Urogynecological Patients with Overactive Bladder.

International urogynecology journal·2026
Same author

Subclinical involvement of central nervous system structures other than motor or sensory tracts in SPG3A and SPG4 patients.

BMC neurology·2026
Same author

Photoluminescence Mechanism and Excited-State Fine Structure of Cs<sub>2</sub>(Na,Ag,K)(In,Bi)Cl<sub>6</sub> Double Perovskite Nanocrystals.

Nano letters·2025
Same author

Alexithymia among patients with obesity - systematic review.

Journal of psychiatric research·2025

Related Experiment Video

Updated: May 21, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Sleep and antidepressant treatment.

Adam Wichniak1, Aleksandra Wierzbicka, Wojciech Jernajczyk

  • 1Third Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland. wichniak@ipin.edu.pl

Current Pharmaceutical Design
|June 12, 2012
PubMed
Summary

Depression disrupts sleep patterns, affecting sleep continuity, slow-wave sleep (SWS), and rapid eye movement (REM) sleep. Some antidepressants worsen sleep, necessitating careful selection and management for patients with depression and insomnia.

More Related Videos

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

Related Experiment Videos

Last Updated: May 21, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

Area of Science:

  • Neuroscience
  • Psychiatry
  • Sleep Medicine

Background:

  • Depression is characterized by significant sleep abnormalities, including disrupted sleep continuity and altered slow-wave sleep (SWS) and rapid eye movement (REM) sleep parameters.
  • Specific sleep changes, like increased REM density and reduced SWS, are valuable biological markers in depression research and antidepressant drug development.

Purpose of the Study:

  • To review sleep anomalies in depression.
  • To examine the impact of antidepressants on sleep.
  • To assess the efficacy of antidepressants for primary insomnia and insomnia in other psychiatric conditions.

Main Methods:

  • Literature review of studies on depression, sleep disturbances, and antidepressant effects.
  • Analysis of sleep parameters (SWS, REM) in depressed individuals.
  • Evaluation of clinical data on antidepressant use for insomnia.

Main Results:

  • Depression is linked to sleep disturbances, though not all changes are specific.
  • Many antidepressants can exacerbate insomnia due to activating effects, requiring co-prescription of sleep aids.
  • Sedative antidepressants (e.g., doxepin, mirtazapine) and circadian-resynchronizing agents (e.g., agomelatine) show promise for insomnia treatment, with doxepin approved for sleep maintenance insomnia.

Conclusions:

  • Antidepressant selection must consider their impact on sleep, balancing efficacy with potential side effects like insomnia.
  • Sedative antidepressants and agents like agomelatine offer therapeutic options for insomnia in psychiatric populations.
  • Further research is needed to support the use of certain antidepressants for primary insomnia, despite existing approvals for specific agents like doxepin.